

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 September 2023 (07.09.2023)



(10) International Publication Number
WO 2023/168176 A1

(51) International Patent Classification:

A61K 31/02 (2006.01) A61K 31/015 (2006.01)
A61K 31/03 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2023/063014

(22) International Filing Date:

22 February 2023 (22.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/315,316 01 March 2022 (01.03.2022) US

(71) Applicant: **KIORA PHARMACEUTICALS GMBH**
[AT/AT]; Reisnerstraße 34/1, 1030 Vienna (AT).

(71) Applicant (for EG only): **KIORA PHARMACEUTICALS, INC** [US/US]; 1371 E 2100 S, Suite 200, Salt Lake City, Utah 84105 (US).

(72) Inventors: **SPERL, Stefan**; Stauraczgasse 7/15, 1050 Wien (AT). **PLASSER, Lisa**; Gumpendorferstraße 41/12, 1060 Wien (AT).

(74) Agent: **WOODHOUSE, Scott M.**; Medler Ferro Woodhouse & Mills PLLC, 8201 Greensboro Dr, Suite 1060, McLean, Virginia 22102 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: SALTS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR




FIG. 1

(57) Abstract: The present disclosure provides salts of 3-(2,3,5,6-tetrafluoro-3'-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid. The present disclosure also provides pharmaceutical compositions comprising salts of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a salt of the invention.

[Continued on next page]

WO 2023/168176 A1

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*